Risk factors

Farmers National Banc Corp added risks related to its completed March 2, 2026 Middlefield merger and federal regulatory changes.

New internal control risks were added following recent restatements. Tariff and trade uncertainties continue to impact raw material costs and international operations. Union contract expiration timelines for manufacturing facilities were updated.

Grid Dynamics added new risk disclosures around geopolitical disruptions, change-of-control contract terminations, and global trade tariff impacts on customers. Artificial intelligence risks were expanded to highlight fast-evolving generative and agentic AI technologies.

Financial losses narrowed to $33.8 million in 2025 with $834.2 million in accumulated deficit.

Grove Collaborative cut its corporate workforce by approximately 30% in November 2025 to reduce SG&A expenses. Net losses narrowed to $11.7 million in 2025 from $27.4 million in 2024. The company completed its migration of its ecommerce platform to third-party technology providers.

Substantial doubt about continuing as a going concern dominates the risks, driven by low cash of $22.0 million at December 31, 2025.

New disclosures highlight risks from artificial intelligence regulations, market expansion, and third-party software dependencies.

Hawthorn Bancshares faces heightened risks from regional economic downturns in central and west-central Missouri and the Kansas City MSA. Fluctuating interest rates threaten net interest income, loan origination, and portfolio values. Credit quality, small-business borrowing vulnerabilities, and broader financial market liquidity are key concerns.

Third-party advertising platforms can change policies, algorithms, pricing, or traffic allocations, affecting revenue and margins.

Increased global potash production forecasts for 2025 and 2026 heighten market oversupply and pricing pressure risks.

Invivyd added new risks regarding its Silicon Valley Bank loan agreement and cash runway of $226.7 million as of year-end 2025. The company updated figures for its federal and state net operating loss carryforwards and detailed ongoing management transitions.

Transitioning from clinical stage to commercial stage following the approval of KOMZIFTI for NPM1-mutated AML in November 2025. Facing new execution, regulatory compliance, co-promotion, and commercialization risks.